Pharma Mar, S.A. (LON:0RC6)

Pharma Mar Statistics

Total Valuation

Pharma Mar has a market cap or net worth of GBP 1.14 billion. The enterprise value is 1.05 billion.

Market Cap	1.14B
Enterprise Value	1.05B

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	Jun 25, 2025

Share Statistics

Current Share Class	17.21M
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	12.04%
Owned by Institutions (%)	9.38%
Float	13.29M

Valuation Ratios

The trailing PE ratio is 38.34 and the forward PE ratio is 25.39.

PE Ratio	38.34
Forward PE	25.39
PS Ratio	7.27
PB Ratio	6.60
P/TBV Ratio	6.64
P/FCF Ratio	77.97
P/OCF Ratio	61.38
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 41.62, with an EV/FCF ratio of 72.22.

EV / Earnings	35.51
EV / Sales	6.75
EV / EBITDA	41.62
EV / EBIT	55.00
EV / FCF	72.22

Financial Position

The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.25.

Current Ratio	2.73
Quick Ratio	2.03
Debt / Equity	0.25
Debt / EBITDA	1.73
Debt / FCF	3.01
Interest Coverage	5.23

Financial Efficiency

Return on equity (ROE) is 17.91% and return on invested capital (ROIC) is 19.47%.

Return on Equity (ROE)	17.91%
Return on Assets (ROA)	4.08%
Return on Invested Capital (ROIC)	19.47%
Return on Capital Employed (ROCE)	8.71%
Weighted Average Cost of Capital (WACC)	6.68%
Revenue Per Employee	312,966
Profits Per Employee	59,363
Employee Count	500
Asset Turnover	0.53
Inventory Turnover	0.19

Taxes

Income Tax	-7.93M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -18.12% in the last 52 weeks. The beta is 0.44, so Pharma Mar's price volatility has been lower than the market average.

Beta (5Y)	0.44
52-Week Price Change	-18.12%
50-Day Moving Average	77.24
200-Day Moving Average	80.44
Relative Strength Index (RSI)	44.91
Average Volume (20 Days)	562

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharma Mar had revenue of GBP 156.48 million and earned 29.68 million in profits. Earnings per share was 1.70.

Revenue	156.48M
Gross Profit	147.93M
Operating Income	19.20M
Pretax Income	21.75M
Net Income	29.68M
EBITDA	23.52M
EBIT	19.20M
Earnings Per Share (EPS)	1.70

Balance Sheet

The company has 128.02 million in cash and 43.93 million in debt, with a net cash position of 84.09 million.

Cash & Cash Equivalents	128.02M
Total Debt	43.93M
Net Cash	84.09M
Net Cash Per Share	n/a
Equity (Book Value)	172.40M
Book Value Per Share	9.89
Working Capital	134.38M

Cash Flow

In the last 12 months, operating cash flow was 18.54 million and capital expenditures -3.94 million, giving a free cash flow of 14.59 million.

Operating Cash Flow	18.54M
Capital Expenditures	-3.94M
Free Cash Flow	14.59M
FCF Per Share	n/a

Margins

Gross margin is 94.53%, with operating and profit margins of 12.27% and 18.97%.

Gross Margin	94.53%
Operating Margin	12.27%
Pretax Margin	13.90%
Profit Margin	18.97%
EBITDA Margin	15.03%
EBIT Margin	12.27%
FCF Margin	9.33%

Dividends & Yields

This stock pays an annual dividend of 0.68, which amounts to a dividend yield of 0.89%.

Dividend Per Share	0.68
Dividend Yield	0.89%
Dividend Growth (YoY)	24.36%
Years of Dividend Growth	6
Payout Ratio	41.02%
Buyback Yield	n/a
Shareholder Yield	0.89%
Earnings Yield	2.61%
FCF Yield	1.28%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on July 22, 2020. It was a reverse split with a ratio of 0.0833333333.

Last Split Date	Jul 22, 2020
Split Type	Reverse
Split Ratio	0.0833333333

Scores

Pharma Mar has an Altman Z-Score of 7.86 and a Piotroski F-Score of 7.

Altman Z-Score	7.86
Piotroski F-Score	7